CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Beclometasone +2 moredrug
Likely dose
Beclometasone 200mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02517099
NCT02517099Phase 2Completed
CompareCT.gov

Use of Pathological Phenotype to Determine Optimal Management for Moderate to Severe Preschool Wheeze

Imperial College London·interventional·Posted Aug 6, 2015·Updated Mar 6, 2023

In Brief

A Phase 2 clinical trial evaluating Beclometasone, Co-amoxiclav, and 1 other intervention for Asthma. Completed, enrolled 60 participants across 1 site.

Detailed Summary

This is a single-centre, randomised-controlled trial, comparing management of preschool wheeze. It specifically aims to compare management of preschool wheeze using current clinical guidelines to management determined by eosinophilic inflammation and infection. Participants will be children aged 1-5 years who have recurrent wheezing and will be allocated to one of two treatment groups, either current clinical care or pathological phenotype based management. They will be asked to make 2 study visits to the Royal Brompton Hospital over the course of 4 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited Kingdom
CollaboratorsNational Institute for Health Research, United Kingdom

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 6, 2015
Enrollment StartJun 5, 2015
Primary CompletionAug 17, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.9 years ago

Interventions

Beclometasonedrug

Beclometasone dipropionate 200mcg bd for 4 months

Co-amoxiclavdrug

Co-amoxiclav 0.3ml/kg bd for 4 weeks

Azithromycindrug

Azithromycin 10mg/kg od for 4 weeks